Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to DO2005000233ApriorityCriticalpatent/DOP2005000233A/en
Publication of DOP2005000233ApublicationCriticalpatent/DOP2005000233A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invencion se refiere a agonistas del receptor nicotinico a7 de formula I como se describen en el presente documento y a un procedimiento para tratar trastornos del Sistema Nervioso Central (SNC) y otros trastornos en un mamifero, incluyendo un humano, administrando al mamifero un agonista del receptor nicotinico a7 de formula I como se muestra en el presente documento. Se refiere tambien a composiciones farnaceuticas que contienen un vehiculo farmaceuticamente aceptable y un agonista del receptor nicotinico a7 penetrante del SNC de formula I.The present invention relates to a7 nicotinic receptor agonists of formula I as described herein and to a method for treating Central Nervous System (CNS) disorders and other disorders in a mammal, including a human, administering to the mammal an agonist. of the a7 nicotinic receptor of formula I as shown herein. It also refers to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS penetrating nicotinic receptor agonist of formula I.
DO2005000233A2005-11-102005-11-10
AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS
DOP2005000233A
(en)
Compounds derived from n - [(2-oxo-1,2-dihydro-3-pyridinyl) methyl] -1h-indole-4-carboxamide, ezh2 inhibitors; pharmaceutical composition that contains them; Useful in the treatment of cancer selected from the group consisting of brain (gliomas), glioblastomas, leukemias and lymphomas, and disorders mediated by the inhibition of ezh2.
Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
Compounds derived from substituted benzofuran, modulators of the igf1 signaling agent or activator of protein kinase b; pharmaceutical composition that includes them; Useful in the treatment of diseases of the CNS, such as Alzheimer's, among others.
Compounds derived from n-substituted azacyclylamines, histamine 3 receptor inhibitors; Preparation process; pharmaceutical composition comprising the compounds, and use for the treatment of cognitive disorders, schizophrenia and Alzheimer's disease among others.
Compounds derived from methoxyphenyl furan-3- (2h) -one, phosphodiesterase 10 (pde10) inhibitors; pharmaceutical composition comprising one of the compounds; and use of the pharmaceutical composition in the preparation of drugs to treat eating disorders, obesity, compulsive gambling, narcolepsy, among others.